Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an update.
Prescient Therapeutics announced an investor briefing to discuss the next phase of their PTX-100 program, following the U.S. FDA’s fast track designation. The company is advancing its oncology pipeline with a planned Phase 2 study for PTX-100 in Cutaneous T cell lymphoma, highlighting its potential impact on cancer treatment and market positioning.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized cancer therapies, including targeted and cellular therapies. Their primary products include PTX-100, a first-in-class compound targeting the cancer growth enzyme GGT-1, and various cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR, which enhance cell therapy performance and provide innovative approaches to cancer treatment.
YTD Price Performance: -16.00%
Average Trading Volume: 506,396
Technical Sentiment Signal: Buy
Current Market Cap: A$33.82M
See more data about PTX stock on TipRanks’ Stock Analysis page.